Avidity Biosciences, Inc. (NASDAQ: RNA), a U.S. small & mid-cap biotechnology company, is making significant strides in developing treatments for genetic diseases.With a focus on rare muscular ...

Sarepta’s partnership with Arrowhead Pharmaceuticals on the ARO-DUX4 program for FSHD is expected to yield superior safety and efficacy results compared to competitors. The unique delivery ...

Fulcrum had identified inhibitors of p38/ mitogen activated protein kinase (MAPK) as powerful inhibitors of DUX4 expression. DUX4 is the gene that is the root cause of FSHD, a progressive muscle ...

The new drug candidate for FSHD will combine an RNA molecule from miRecule targeting double homeobox 4 (DUX4) – a protein that is mutated in FSHD – with a nanobody developed by Sanofi that ...

Products Market Alerts MyCollection Price Database Become a Partner Gallery ...

At close: 18 June at 16:00:01 GMT-4 ...